The major aims of CORVOS are the discovery of therapeutic ways to support or inhibit the action of complement and to interfere with its abuse by pathogens and the training of young scientists for academia and industry.
“We will enrol two PhD students that will work and study towards a double PhD degree from both Lund University and Utrecht University. This initiative will in the long run provide conditions for better research, new collaborations and network, high quality PhD education for the involved student and internalization for Lund University”, says Anna Blom, Professor of Lund University participating in the CORVOS initiative.
CORVOS will in total educate fifteen highly motivated PhD students to fill the current scientific gap in the understanding of the role of complement in opportunistic infections. The young scientists will become creative alumni equipped with entrepreneurial and clinical skills, making them attractive human resources to academia and industry alike.
The European Union finances the programme which is coordinated by the Medical University of Innsbruck. CORVOS was approved in May 2019 and officially started 1 December the same year. It is financed by the Horizon2020 project of the European Commission. The acronym CORVOS stands for COmplement Regulation and Variations in Opportunistic infectionS.
More information about CORVOS on their webpage.
Participating partners of CORVOS
Universities:
- Medical University of Innsbruck (AT)
- Lund University (SE)
- University of Lübeck (DE)
- Humanitas University Milano (IT)
- Utrecht University (NL)
- University of Helsinki (FI)
- Sorbonne University Paris (FR)
- University of Copenhagen (DK)
- University of Oslo (NO)
- Semmelweis University Budapest (HU)
Research institutes/public health bodies:
- Research Center Borstel (DE)
- Statens Serum Institut (DK)
- Region H (DK)
- University Medical Center Utrecht (NL)
- Institute national de la santé et de la recherche médicale – INSERM (FR)
Biomedical companies:
Hospitals: